Network analysis of grade II into grade III transition in rectum cancer patients

Mohammad Rostami-Nejad¹, Vahid Mansouri², Reza Mahmoud Robati³, Hamid Mohaghegh Shalmani¹, Reza Mahmoudi Lamouki⁴, Mostafa Rezaei Tavirani²

¹Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
²Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
³Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
⁴Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

ABSTRACT

Aim: Finding important differential genes between grade II and grade III of rectum cancer was the aim of this study.
Background: Colorectal (CRC) cancers (CRC) are known as the third diagnosed cancer and the second leading to death cancers. Life style is an important risk factor of CRCs. Diagnosis of rectum cancer estimated as 44% of colon cancer.
Methods: Differentially expressed genes (DEGS) related to grade II into grade II in 6 patients are retrieved from gene expression omnibus (GEO) and investigated by protein-protein interaction (PPI) network analysis. Central nodes of the network are identified and enriched to determine biochemical pathways. Action map is illustrated for the central genes.
Results: Among 15 central genes including AKT1, PRDM10, GAPDH, TP53, SRC, EGFR, ALB, INS, CTNNB1, EGF, IL6, RHOA, DECR1, ACACA, GMPS role of AKT1 is highlighted due to prominent role in the integrity of the network and participation in the most determined pathways. However, significant regulatory effect of INS, AKT1, EGF, EGFR, and CTNNB1 is tinted in action map.
Conclusion: It seems that AKT1, EGFR, and TP3 are suitable drug targets to prevent rectum cancer progression.

Keywords: Rectum, Cancer, Gene, Protein.

Introduction

Colorectal cancers (CRC) are classified as the third diagnosed cancer and the second leading to death among cancers. Investigation indicates that special lifestyle is an important risk factor of CRCs. High fruit and vegetable diet, maintenance of body weight, in oppose with Tobacco consuming, high red meat diet, type II diabetes mellitus, aging, and family history of CRC reduce the risk of CRCs. However, sex is counted as risk factor of CRC, an investigation attributed it to common pathway of colon cancer and breast cancer in women (1, 2). Numbers of 43030 individuals including 25920 male and 17110 female estimated new cases with rectum cancer were reported in US in 2018. In this report, the amount of rectum cancer in patients were estimated as 44% of colon cancer patients (3). Since treatment of cancer in advanced stages is difficult, early detection of disease or at least in the lower stages is a main effort in clinic (4).

High through output methods like proteomics and genomics are used frequently to detect biomarkers related to early stages of different cancers (5, 6). In this case, large numbers of differentially expressed genes
(DEGS) are highlighted and the dependent metabolites or proteins are analyzed (7). There is a useful method to screen the introduced differential agents to find the best and relevant ones to the disorder. This method is PPI network analysis which is able to interact the query genes (or protein and also metabolites) in a interacted unit as interactome (8). Central properties of interactome or network differentiate the interacted genes and it is possible to extract critical genes among the large numbers of query genes (9). Degree, betweenness centrality, and closeness centrality are three important central parameters of the nodes (10). In this approach, it is possible that regulatory effects of genes on each other be investigated. Activation, inhibition, and also expression regulation including up and down-regulations are three action features of the studied genes which can be identified in network analysis (11). In this study differential expressed genes that distinct grade II and grade III rectum cancer are evaluated by PPI network analysis to find possible drug targets to prevent grade II into grade III transition in the rectum cancer patients.

Methods

Gene Expression Omnibus database is a valuable source of gene expression data. Gene expression profile of 6 individual’s samples characterized by GSE25071/GPL2986 were acquired. Gene expression profiles of three grade II rectum cancer patients including two female (53 and 48 years old) and a 44 years old male and three grade III rectum cancer patients including two female (41 and 45 years old) and a 40 years old male have been chosen. The samples are presented as GSM615925, GSM615933, GSM615946, GSM615941, GSM615947, and GSM615929. The top 250 significant and characterized top DEGs were selected and interacted via PPI network analysis by STRING and the network including 44 isolated relationships related to the central nodes was constructed via CluePedia. Biochemical pathways associated to the central nodes were introduced from KEGG by ClueGO. Distribution of central nodes among the pathways was analyzed. Interaction pattern of central nodes was prepared by Cytoscape.

Results

The 6 samples were matched via box plot analysis by GEO2R (see figure 1). The gene expression profiles are median centered, therefore they are comparable. As it is depicted in the figure 1 the quarters show approximately symmetry.

![Figure 1. Box plot comparison of samples via GEO2R.](image)

Numbers of 250 top significant DEGs based on p-value < 0.05 were considered to further analysis. Change fold of all DEGs was less than 0.5 and more than 2. It was appeared that 60 DEGs were not characterized. 100 relevant genes were added to 190 characterized DEGs to construct interacted unit 286 nodes were recognized by STRING and the network including 44 isolated
genes, one paired nodes and a main connected component (contains 240 nodes and 3893 edges) was built (Figure 2). Degree distribution was fitted on $y = ax^b$ equation where $a$ and $b$ were 11.865 and -0.459, respectively. Correlation and R-squared (computed on logarithmized values) were 0.870 and 0.458, respectively. As it is shown in the table 1, 5 hub nodes and 12 bottlenecks (top nodes based on betweenness centrality value) are identified. Surprisingly, all the bottlenecks are top nodes based on closeness centrality and only there are two hub-bottlenecks. Action network regarding 15 central nodes (characterized by top values of degree, betweenness, and closeness centralities) is shown in the figure 3. Expression action including up –
regulation and down-regulation, activation and inhibition actions are illustrated in this map. 13 biochemical pathways related to the central nodes are determined; however, only 11 genes among 15 central individuals are involved (Table 2). Distribution of central nodes among biochemical pathways is tabulated in table 3.

### Table 2. Biochemical pathways (analyzed by ClueGO) related to the central nodes were found in KEGG_20.11-2017. \%G/T and G/T refer to percentage of gene contribution in TEM and gene per term, respectively.

| R  | GO Term                             | GO Groups | \% G/T | G/T | Associated Genes Found                      |
|----|------------------------------------|-----------|--------|-----|---------------------------------------------|
| 1  | HIF-1 signaling pathway            | Group0    | 6.00   | 6   | [AKT1, EGF, EGFR, GAPDH, IL6, INS]          |
| 2  | Adherens junction                  | Group1    | 5.56   | 4   | [CTNNB1, EGFR, RHOA, SRC]                   |
| 3  | Prolactin signaling pathway        | Group2    | 4.29   | 3   | [AKT1, INS, SRC]                            |
| 4  | Colorectal cancer                  | Group3    | 5.56   | 4   | [AKT1, CTNNB1, RHOA, TP53]                  |
| 5  | ErbB signaling pathway             | Group4    | 4.65   | 4   | [AKT1, EGF, EGFR, SRC]                      |
| 6  | Pancreatic cancer                  | Group4    | 5.33   | 4   | [AKT1, EGF, EGFR, TP53]                     |
| 7  | Endometrial cancer                 | Group4    | 8.62   | 5   | [AKT1, CTNNB1, EGF, EGFR, TP53]             |
| 8  | Glioma                             | Group4    | 5.63   | 4   | [AKT1, EGF, EGFR, TP53]                     |
| 9  | Prostate cancer                    | Group4    | 6.19   | 6   | [AKT1, CTNNB1, EGF, EGFR, INS, TP53]        |
| 10 | Melanoma                           | Group4    | 5.26   | 4   | [AKT1, EGF, EGFR, TP53]                     |
| 11 | Bladder cancer                     | Group4    | 9.76   | 4   | [EGF, EGFR, SRC, TP53]                      |
| 12 | Non-small cell lung cancer         | Group4    | 6.06   | 4   | [AKT1, EGF, EGFR, TP53]                     |
| 13 | Central carbon metabolism in cancer| Group4    | 4.62   | 3   | [AKT1, EGFR, TP53]                          |

### Discussion
Molecular mechanism of wide varieties of diseases is investigated via PPI network analysis and among large numbers of differential agents as like genes, proteins, and metabolites, few numbers with high impact on onset and development of diseases are identified. The
introduced high impact biomolecules are suitable candidates for biomarker discovery (14, 15). In this study gene expression profiles of three grade III rectum cancer patients are compared with three ones in grade II. As it is shown, samples are matched statistically.

Table 3. Distribution of central nodes among biochemical pathways.

| R | Gene name       | Number of pathways |
|---|-----------------|--------------------|
| 1 | AKT1, EGFR,     | 11                 |
| 2 | EGF, TP53       | 9                  |
| 3 | CTNNB1          | 4                  |
| 4 | INS, SRC        | 3                  |
| 5 | RHOA            | 2                  |
| 6 | GAPDH, IL6      | 1                  |

As it is shown in the figure 2 and table 1, network analysis revealed that 15 central nodes are involved in grade II into grade III transition in rectum cancer. Except AKT1 and PRDM10 the other nodes are hubs or central nodes based on closeness and betweenness centralities. Action map which is illustrated in the figure 3 showed that GMPS and DECR1, that are weak central nodes, have no regulatory effect on the other ones. PRDM10 the second hub-bottleneck has single activation edge on ACACA but the others interacted via compact activation, inhibition, and expression action with each other. As it is shown in table 2, 13 biochemical pathways in 5 groups are identified which are related to the central nodes. Group 3 includes only one pathway which is determines as colorectal cancer. AKT1, CTNNB1, RHOA, and TP53 are the four central genes (the genes wit high values of centrality parameters) that are involved in this pathway. For better understanding distribution of central nodes in pathways is shown in the table 3. Only 10 genes among 15 central nodes including AKT1, EGFR, EGF, TP53, CTNNB1, INS, SRC, RHOA, GAPDH, and IL6 are involved in the pathways. AKT1, EGFR, EGF, and TP53 have the most participation in the pathways. It seems that AKT1 plays crucial role in transition of grade II rectum cancer into grade II. Inhibition effect of AKT1 on TP53 and INS is highlighted in the figure 3. In many studies it is emphasized that loss of functional role of TP53 is a frequent event in cancer onset and development (16, 17). INS is an important metabolic hormone and is responsible for anabolic signals that promote tumor development. There is evidence that hyperinsulinemia is related to colon cancer. Bioactivity of insulin like growth factor-I increases by insulin. It is reported that this growth factor promotes CRC (18). However, inhibition of TP53 by AKT1 is corresponded with the oncogenic role of AKT1 but inhibition of insulin which plays a positive role in development of CRC by AKT1 is a paradox. To solve this paradox, we returned to the figure 3, AKT1 inhibits insulin while insulin activates AKT1. This relationship between AKT1 and insulin indicates that insulin promotes its oncogenic property via oncogene mediators such as AKT1. In a negative feedback AKT1 inhibits insulin. Considering this prominent role of insulin in rectum cancer, it can be concluded that the factors which increase insulin biosynthesis and secretion indirectly are involved in rectum cancer promotion. The main element in regulation of insulin level in body is glucose. Investigations indicate that glucose can elevate insulin level in blood by 4 fold. Beside this direct effect of glucose on insulin biosynthesis and secretion, it is found that high level of glucose leads to more stabilization of insulin mRNA which its stability is lower in the normal condition (19). This finding consists with the impact of lifestyle on onset of rectum cancer. EGFR which transmits cell growth signals, plays significant role in cancer development. TGFα and EGF stimulate EGFR to induce cell growth signaling in normal condition and are involved in invasive and metastatic condition of cancers (20). Therefore, appearing of EGFR and its ligand EGF as crucial elements of rectum cancer is not a surprising finding. As it is shown in table 2, 6 numbers of central genes including AKT1, EGFR, GAPDH, IL6 and INS are involved in hypoxia inducible factor-1 signaling pathway. This combination of central genes relative to the enriched pathways includes maximum numbers of central genes. This pathway is responsible for delivery of oxygen and increment level of HIF-1 is correlated to tumor metastasis and angiogenesis. In response to hypoxia in tumors HIF-1 level increases (21). In conclusion it seems that AKT1, EGFR, and TP3 are suitable drug targets to prevent rectum cancer progression. The other point is high impact of lifestyle especially diet regime which play crucial role in regulation of main players in the field of rectum cancer.

Acknowledgment

This research is supported by Shahid Beheshti University of Medical Sciences.
Conflict of interests
The authors declare that they have no conflict of interest.

References
1. Ansa BE, Coughlin SS, Aleva-Mensah E, Smith SA. Evaluation of Colorectal Cancer Incidence Trends in the United States (2000–2014). J Clin Med 2018;7:22.
2. Zamanian-Azodi M, Rezai-Tavirani M, Rahmati-Rad S, Hasanazadeh H, Tavirani MR, Seyyedi SS. Protein-Protein Interaction Network could reveal the relationship between the breast and colon cancer. Gastroenterol Hepatol Bed Bench 2015;8:215.
3. Norouzinia M, Asadzadeh H, Shalmani HM, Al Dulaimi D, Zali MR. Clinical and histological indicators of proximal and distal gastric cancer in eight provinces of Iran. Asian Pac J Cancer Prev. 2012;13:5677-9.
4. Nazemalhosseini Mojarad E, Kashfi SM, Mirtalebi H, Taleghani MY, Azimzadeh P, Savabkar S, et al. Low Level of Microsatellite Instability Correlates with Poor Clinical Prognosis in Stage II Colorectal Cancer Patients. J Oncol. 2016;2016:2196703.
5. Rostami Nejad M, Ishaq S, Al Dulaimi D, Zali MR, Rostami K. The role of infectious mediators and gut microbiome in the pathogenesis of celiac disease. Arch Iran Med. 2015;18:244-49.
6. Nazemalhosseini Mojarad E, Kuppen PJ, Aghdai HA, Zali MR. The CpG island methylator phenotype (CIMP) in colorectal cancer. Gastroenterol Hepatol Bed Bench. 2016;2016:2196703.
7. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J cancer 2010;127:118-26.
8. Lakri P, Gharib E, Yaghoob Taleghani M, Khoshid H, Nazemalhosseini-Mojarad E, Asadzadeh Aghdai H. Coexistence of KRAS and BRAF Mutations in Colorectal Cancer: A Case Report Supporting The Concept of Tumoral Heterogeneity. Cell J. 2017;19:113-117.
9. Maghvan PV, Rezaei-Tavirani M, Zali H, Nikzamir A, Abd S, Khoddostan M, et al. Network analysis of common genes related to esophageal, gastric, and colon cancers. Gastroenterol Hepatol Bed Bench 2017;10:295.
10. Karbalaei R, Piran M, Rezaei-Tavirani M, Asadzadeh-Aghdai H, Heidari MH. A systems biology analysis protein-protein interaction of NASH and IBD based on comprehensive gene information. Gastroenterol Hepatol Bed Bench 2017;10:194.
11. Bindea G, Galon J, Mlecnik B. CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data. Bioinformatics 2013;29:661-3.
12. Nazemalhosseini Mojarad E, Farahani RK, Haghighi MM, Aghdai HA, Kuppen PJ, Zali MR. Clinical implications of BRAF mutation test in colorectal cancer. Gastroenterol Hepatol Bed Bench. 2013;6:6-13.
13. Zamanian Azodi M, Peyvandi H, Rostami-Nejad M, Safaei A, Rostami K, Vafaee Ret al. Protein-protein interaction network of celiac disease. Gastroenterol Hepatol Bed Bench. 2016;9:268-277.
14. Rostami Nejad M, Rostami K, Cheraghipour K, Nazemalhosseini Mojarad E, Volta U, Al Dulaimi D, et al. Celiac disease increases the risk of toxoplasma gondii infection in a large cohort of pregnant women. Am J Gastroenterol. 2011;106:548-9.
15. Engin HB, Guney E, Keskin O, Oliva B, Gursoy A. Integrating structure to protein–protein interaction networks that drive metastasis to brain and lung in breast cancer. Plos One 2013;8:e81035.
16. Rostami Nejad M, Nazemalhosseini Mojarad E, Nochi Z, Fasihri Harandi M, Cheraghipour K, Mowlavi GR, et al. Echinococcus granulosus strain differentiation in Iran based on sequence heterogeneity in the mitochondrial 12S rRNA gene. J Helminthol. 2008;82:343-47.
17. Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N, et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 2005;23:7518-28.
18. Tajbakhsh M, Garcia Migura L, Rahbar M, Svendsen CA, Mohammadzadeh M, et al. Antimicrobial-resistant Shigella infections from Iran: an overlooked problem? J Antimicrob Chemother. 2012;67:1128-33.
19. Fu Z, R Gilbert E, Liu D. Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes. Curr Diabetes Rev 2013;9:25-53.
20. Sasaki T, Hiroki K, Yamashita Y. The role of epidermal growth factor receptor in cancer metastasis and microenvironment. Bio Med Res Int 2013;2013.
21. Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B 2015;5:378-89.